To review the pharmacology, mycology, chemistry, in vitro susceptibility, pharmacokinetics, clinical efficacy, safety, tolerability, dosage, and administration of micafungin, an echinocandin antifungal agent.
DATA SOURCES
A MEDLINE search, restricted to English language, was conducted from 1978 to November 2003. Supplementary sources included program abstracts from the Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America from 1996 to 2003 and information available through the manufacturer's Web site.
STUDY SELECTION AND DATA EXTRACTION
In vitro and preclinical studies, as well as Phase II and III clinical trials, were evaluated to summarize the clinical efficacy and safety of micafungin. All published and unpublished trials and abstracts citing micafungin were selected.
DATA SYNTHESIS
Micafungin has shown in vitro activity against many yeasts and a variety of molds. Micafungin can be administered only parenterally. Efficacy has been illustrated in open noncomparative studies of esophageal candidiasis in HIV-infected patients and in comparative trials as antifungal prophylaxis in patients undergoing hematopoietic stem-cell transplantation. Adverse events appear mild and limited; the most commonly reported adverse events include hyperbilirubinemia, nausea, and diarrhea.
CONCLUSIONS
Micafungin has activity against Aspergillus spp. and a variety of Candida spp., including azole-resistant strains. Micafungin demonstrates efficacy in the treatment of esophageal candidiasis in HIV-infected patients and appears superior to fluconazole as antifungal prophylaxis in patients undergoing hematopoietic stem-cell transplantation. Based on case reports and in vitro efficacy, micafungin may prove to be a clinically useful agent in the treatment of other fungal diseases; however, these indications await the results of clinical trials.
. TrickWEFridkinSKEdwardsJRHajjehRAGaynesRP.Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin Infect Dis2002;35:627–30.
2.
. PfallerMAJonesRNDoernGVSaderHSHollisRJMesserSA.International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada and South America for the SENTRY Program. J Clin Microbiol1998;36:1886–9.
3.
. RexJH.Candins (abstract 1123). In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September17–20, 2000.
4.
. TomishimaMOhkiHYamadaATakasugiHMakiKTawaraSFK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity. J Antibiot (Tokyo)1999;52:674–6.
5.
. MakiKMorishitaYIguchiYWatabeEOtomoKTerataniNIn vitro antifungal activity of FK463, a novel water-soluble echinocandin-like lipopeptide (abstract F-141). In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September24–27, 1998.
. Press release: Fujisawa changes its expectation for approval timing of micafungin, a candin antifungal agent, in US. Fujisawa Healthcare, Inc., February 3, 2003. http://fujisawa.co.jp/english/ir/release/e030203.pdf (accessed 2003Jun10).
. TawaraSIkedaFMakiKMorishitaYOtomoKTerataniNIn vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother2000;44:57–62.
10.
. MikamoHSatoYTamayaT.In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J Antimicrob Chemother2000;46:485–7.
11.
. NishiyamaYUchidaKYamaguchiH.Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide. J Electron Microscopy2002;51:247–55.
12.
. HatanoKMorishitaYNakaiTIkedaF.Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. J Antibiot (Tokyo)2002;55:219–22.
13.
. ChiouCCMavrogiorgosNTillemEHectorRWalshTJ.Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob Agents Chemother2001;45:3310–21.
14.
. PetraitisVPetraitieneRGrollAHRoussillonKHemmingsMLymanCAComparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother2002;46:1857–69.
15.
. NakaiTUnoJIkedaFTawaraSNishimuraKMiyajiM.In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob Agents Chemother2003;47:1376–81.
16.
. NakaiTUnoJOtomoKIkedaFTawaraSGotoTIn vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds. Chemotherapy2002;48:78–81.
17.
. Borg-von ZepelinMZaschkeKGrossUMonodMMullerFM.Effect of micafungin (FK463) on Candida albicans adherence to epithelial cells. Chemotherapy2002;48:148–53.
18.
. KuhnDMGeorgeTChandraJMukherjeePKGhannoumMA.Anti-fungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother2002;46:1773–80.
19.
. NakaiTHatanoKIkedaF.Electron microscopic findings for micafungin-treated pulmonary aspergillosis in mice (abstract M-1511). In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September27–30, 2002.
20.
. StevensDA.Susceptibility to micafungin (M) of isolates from clinical trials (abstract M-1520). In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September27–30, 2002.
21.
. UchidaKNishiyamaYYokotaNYamaguchiH.In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J Antibiot (Tokyo)2000;53:1175–81.
22.
. TakakuraSFujiharaNSaitoTKudoTIinumaYIchiyamaS.National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother2004;53:283–9.
23.
. Ostrosky-ZeichnerLRexJHPappasPGHamillRJLarsenRAHorowitzHWAntifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother2003;47:3149–54.
24.
. Ostrosky-ZeichnerLPaetznickVLSancakBRodriguezJRChenERexJH.Correlation of minimum inhibitory concentrations (MIC) and disk diffusion inhibition diameters (DDID) for FK-463 in 403 blood stream isolates of Candida spp (abstract J-572). In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December16–19, 2001.
25.
. LaverdiereMHobanDRestieriCHabelF.In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother2002;50:119–23.
26.
. MullerFMKurzaiOHackerJFroschMMuhlschlegelF.Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis. J Antimicrob Chemother2001;48:713–5.
27.
. Ostrosky-ZeichnerLPaetznickVLMohrJRodriguezJRChenESancakBIn vitro antifungal activity of FK-463 against Candida spp (abstract 197). In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September17–20, 2000.
28.
. MooreCBDenningDW.Tolerance and fungicidality in vitro of caspofungin, micafungin and anidulafungin against Candida guilliermondii (abstract M-230). In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September27–30, 2002.
29.
. MaesakiSHossainMAMiyazakiYTomonoKTashiroTKohnoS.Efficacy of FK463, a (1,3)-β-d-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice. Antimicrob Agents Chemother2000;44:1728–30.
30.
. NeelyMNGhannoumMA.Colorimetric enhancement of NCCLS M27 protocol for anti-fungal MIC determination (abstract 927). In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September17–20, 2000.
31.
. KurtzMBHeathIBMarrinanJDreikornSOnishiJDouglasC.Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-d-glucan synthase. Antimicrob Agents Chemother1994;38:1480–9.
32.
. YamaguchiHUchidaKKumeHShinodaTWatanabeKKusunokiTReport of the Committee of Clinical Laboratory Standards—1004. Jpn J Med Mycol1995;36:61–86.
33.
. IkedaFWakaiYMatsumotoSMakiKWatabeETawaraSEfficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother2000;44:614–8.
34.
. RexJHWalshTJSobelJDFillerSGPappasPGDismukesWEPractice guidelines for the treatment of candidiasis. Clin Infect Dis2000;30:662–78.
35.
. ImhofABalajeeSAMarrKA.New methods to assess susceptibilities of Aspergillus isolates to caspofungin. J Clin Microbiol2003;41:5683–8.
36.
. ArikanSYurdakulPHascelikG.Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp. Antimicrob Agents Chemother2003;47:2640–3.
37.
. WatabeENakaiTMatsumotoSIkedaFHatanoK.Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability. Antimicrob Agents Chemother2003;47:1995–8.
38.
. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard M27–A. Villanova, PA: National Committee for Clinical Laboratory Standards, 1997.
39.
. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Proposed standard M38–P. Villanova, PA: National Committee for Clinical Laboratory Standards, 1998.
40.
. ErnstEJRolingEEPetzoldCRKeeleDJKlepserME.In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemother2002;46:3846–53.
41.
. SerenaCOrtonedaMCapillaJPastorFJSuttonDARinaldiMGIn vitro activities of new antifungal agents against Chaetomium spp. and inoculum standardization. Antimicrob Agents Chemother2003;47:3161–4.
42.
. ItoMNozuRKuramochiTEguchiNSuzukiSHiokiKProphylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice. Antimicrob Agents Chemother2000;44:2259–62.
43.
. KurtzMBAbruzzoGFlatteryABartizalKMarrinanJALiWCharacterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect Immunity1996;64:3244–51.
44.
. BachmannSPPattersonTFLopez-RibotJL.In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol2002;40:2228–30.
. ManavathuEKRameshMSBaskaranIGanesanLTChandrasekarPH.A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother2004;53:386–9.
47.
. NakaiTWatabeEOtomoKHatanoKIkedaF.In vitro pharmacodynamic characterization of micafungin against 5 different Candida species (abstract A-494). In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September27–30, 2002.
48.
. MatsumotoSWatabeEWakaiYKoideYUshitaniTTerataniNPharmacodynamics of FK463 in a thigh infection model with Candida albicans (abstract 1687). In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September17–20, 2000.
49.
. MukaiTOhkumaTNakaharaKTakayaTUematsuTAzumaJ.Pharmacokinetics of FK463, a novel echinocandin analogue, in elderly and non-elderly subjects (abstract A-30). In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December16–19, 2001.
50.
. SeibelNSchwartzCArrietaAFlynnPShadAAlbanoEA Phase 1 study to determine the safety and pharmacokinetics (pk) of FK463 (echinocandin) in febrile neutropenic pediatric patients (abstract 18). In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September17–20, 2000.
51.
. HiemenzJCagnoniPSimpsonDDevineSChaoN.Maximum tolerated dose and pharmacokinetics of FK463 in combination with fluconazole for the prophylaxis of fungal infections in adult bone marrow or peripheral stem cell transplant patients (abstract 1648). In: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September26–29, 1999.
52.
. AzumaJYamamotoIOguraMMukaiTSuematsuHKageyamaHPhase I study of FK463, new antifungal agent, in healthy adult male volunteers (abstract F-146). In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September24–27, 1998.
. TownsendRHebertMDessimozMWisemandleWBekerskyI.Pharmacokinetics (PK) of micafungin, an echinocandin antifungal, in subjects with moderate hepatic dysfunction (MHD) (abstract 16). J Clin Pharmacol2002;42:1054.
55.
. TownsendRHebertMDessimozMWisemandleWBekerskyI.Pharmacokinetics (PK) of micafungin, an echinocandin antifungal, in subjects with severe renal dysfunction (abstract 17). J Clin Pharmacol2002;42:1054.
56.
. PetraitisVPetraitieneRSarafandiAAKelaherAMLymanCACaslerHECombination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis2003;187:1834–43.
57.
. PacettiSAGeloneSP.Caspofungin acetate for treatment of invasive fungal infections. Ann Pharmacother2003;37:90–8. DOI 10.1345/aph.1C114.
58.
. TownsendRHebertMWisemandleWBekerskyI.Concomitant pharmacokinetics (PK) of micafungin, an echinocandin antifungal, and cyclosporine in healthy volunteers (abstract 15). J Clin Pharmacol2002;42:1055.
59.
. TownsendRHebertMWisemandleWBekerskyI.Concomitant pharmacokinetics (PK) of micafungin, an echinocandin antifungal, and tacrolimus in healthy volunteers (abstract 18). J Clin Pharmacol2002;42:1055.
60.
. Van BurikJRatanatharathornVLiptonJMillerCBuninNWalshTJ.Randomized, double-blind trial of micafungin (MI) versus fluconazole (Fl) for prophylaxis of invasive fungal infections in patients (pts) undergoing hematopoietic stem cell transplant (HSCT), NIAID/BAMSG protocol 46 (abstract M-1238). In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September27–30, 2002.
61.
. PettengellKMynhardtJKluytsTSimjeeABaraldiE.A multicenter study of the echinocandin antifungal FK463 for the treatment of esophageal candidiasis in HIV positive patients (abstract 1104). In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September17–20, 2000.
62.
. SuleimanJDella NegraMLlanos-CuentasATiconaERexJHBuellDN.Open label study of micafungin in the treatment of esophageal candidiasis (EC) (abstract M-892). In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September27–30, 2002.
63.
. PettengellKMynhardtJKluytsTLauWFacklamDBuellDSuccessful treatment of esophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol2004;20:475–81.
64.
. KohnoSMasaokaTYamaguchiHMoriTUrabeAItoAA multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis2004;36:372–9.
65.
. KontoyiannisDPBuellDFrisbee-HumeSReddyBTRolstonKV.Initial experience with FK463 for the treatment of candidemia in cancer patients (abstract J-1629). In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December16–19, 2001.
66.
. GraybillJR.The echinocandins, first novel class of antifungals in two decades: will they live up to their promise?Int J Clin Pract2001;55:633–8.
67.
. RatanatharathornVFlynnPVan BurikJAMcSweeneyPNiederwieserDKontoyannisD.Micafungin in combination with systemic antifungal agents in the treatment of refractory aspergillosis in bone marrow transplant patients (abstract 2472). In: Program and abstracts of the American Society of Hematology 44th annual meeting, Philadelphia, 2002.
68.
. FK 463. Drugs1999;2:172–3.
69.
. PowlesRSirohiBChopraRRusselNPrenticeHG.Assessment of maximum tolerated dose (MTD) of FK463 in cancer patients undergoing haematopoietic stem cell transplantation (abstract J-676). In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December16–19, 2001.
70.
. PowlesRSirohiBChopraRRusselNPrenticeHG.Use of FK 463, a novel echinocandin analog in patients undergoing autologous or allogeneic stem cell transplantation for haematologic malignancies, a matched pair comparison of biochemical toxicity with historical controls (abstract 867–I). Blood2001;98:867.
